Summaries & Associations of Study Results
TR-434 1,3-Butadiene
Target Organs and Levels of Evidence
NTP Technical Report Number 434
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| 1,3-BUTADIENE 106-99-0 |
11/21/91 | CHEMICAL INTERMEDIATE. MANUFACTURE OF SYNTHETIC RUBBER. PRODUCED FROM PETROLEUM GASES (MERCK 1989) | Inhalation 0, 6.25, 20, 62.5, 200, 625 PPM/50 PER GROUP | Battelle Northwest Laboratory |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MM: CLEAR EVIDENCE | HEMATOPOIETIC SYSTEM: LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50 | |||
| VASCULAR SYSTEM (HEART): HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50 | ||||
| LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50 | ||||
| FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50 | ||||
| LIVER: ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50 | ||||
| HARDERIAN GLAND: ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50 | ||||
| PREPUTIAL GLAND: CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50 | ||||
| KIDNEY TUBULAR CELL: ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50 | ||||
| BRAIN: (STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50 | ||||
| MAY HAVE BEEN RELATED: | INTESTINES: CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73 | |||
| ZYMBAL GLAND: (STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50 | ||||
| NON-NEOPLASTIC LESIONS: | BONE MARROW: ATROPHY | |||
| HEART: ENDOTHELIAL HYPERPLASIA, MINERALIZATION; (STOP STUDY) ENDOTHELIAL HYPERPLASIA, MINERALIZATION | ||||
| LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA; (STOP STUDY) ALVEOLAR EPITHELIAL HYPERPLASIA | ||||
| FORESTOMACH: EPITHELIAL HYPERPLASIA; (STOP STUDY) EPITHELIAL HYPERPLASIA | ||||
| HARDERIAN GLAND: HYPERPLASIA; (STOP STUDY) HYPERPLASIA | ||||
| TESTICLE: ATROPHY; (STOP STUDY) ATROPHY | ||||
| FM: CLEAR EVIDENCE | HEMATOPOIETIC SYSTEM: LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80 | |||
| VASCULAR SYSTEM (HEART): HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80 | ||||
| LUNG: ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78 | ||||
| FORESTOMACH: SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80 | ||||
| LIVER: ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80 | ||||
| HARDERIAN GLAND: ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80 | ||||
| OVARY: BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79 | ||||
| MAMMARY GLAND: ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80 | ||||
| MAY HAVE BEEN RELATED: | KIDNEY TUBULAR CELL: ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80 | |||
| SUBCUTANEOUS TISSUE: NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80 | ||||
| ZYMBAL GLAND: ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80 | ||||
| NON-NEOPLASTIC LESIONS: | BONE MARROW: ATROPHY | |||
| HEART: ENDOTHELIAL HYPERPLASIA; MINERALIZATION | ||||
| LUNG: ALVEOLAR EPITHELIAL HYPERPLASIA | ||||
| FORESTOMACH: EPITHELIAL HYPERPLASIA | ||||
| LIVER: FOCI | ||||
| HARDERIAN GLAND: HYPERPLASIA | ||||
| OVARY: ANGIECTASIS; GRANULOSA CELL HYPERPLASIA; GERMINAL EPITHELIAL HYPERPLASIA; ATROPHY | ||||
| UTERUS: ATROPHY | ||||
Web page last updated on February 10, 2006
